What specialist importers are telling us about preparedness, shortages and patient care
Over the past few months, I’ve had a series of conversations with specialist wholesalers and unlicensed importers working across the UK and Europe.
Different companies, different portfolios but strikingly similar challenges.
What follows isn’t a product pitch. It’s a set of recurring insights that keep coming up when we talk about shortages, unlicensed supply, and continuity of patient care.
1. Shortages rarely begin where they are declared
One of the strongest themes from these discussions is that shortages are almost never the starting point.
By the time a Shortage Notification is issued, most importers told us they are already hearing about problems elsewhere
-
Manufacturing or API constraints reported overseas
-
Export controls or quota restrictions in EU markets
-
Localised stock pressure in hospitals or pharmacies
In other words, the signal appears internationally first even though the impact is ultimately felt in the UK.
2. Unlicensed imports protect continuity - but only if preparation starts early
Every specialist importer I’ve spoken to sees unlicensed medicines as essential to maintaining continuity of care during UK shortages.
But there was also strong agreement on this point:
Unlicensed supply cannot be improvised at the moment of crisis.
Because MHRA approval depends on a formally recognised UK issue, importers are not talking about supplying in parallel with licensed products.
They are talking about being ready.
That preparation typically includes
-
Identifying credible overseas sources
-
Assessing quality, presentation and comparability
-
Understanding regulatory pathways and constraints
-
Preparing clinical and logistical documentation
-
Mapping realistic lead times and volumes
All of it shortens the time to supply once it is permitted.
3. Preparation is constrained by visibility
A consistent frustration I’ve heard is that preparation often starts too late — not because teams are complacent, but because risk is hard to see early.
When intelligence is limited to UK-facing signals:
-
Importers wait for formal confirmation before mobilising
-
Sourcing options narrow rapidly once shortages are public
-
Regulatory and logistics teams are pulled into reactive mode
Several teams described this as being “technically compliant, but operationally behind.”
4. Why non-UK market intelligence matters - even with UK-only approvals
One point that came up repeatedly surprised some people outside the sector:
Even though imports cannot proceed until a UK issue is declared, the preparation work depends on non-UK markets.
Specialist importers told us that real-time visibility outside the UK helps them:
-
Judge whether a potential UK shortage is transient or structural
-
Focus preparation on markets likely to remain viable sources
-
Avoid wasted effort chasing regions already under strain
-
Align internal planning with realistic sourcing scenarios
This isn’t about circumventing regulation.
It’s about ensuring that, when approval comes, options still exist.
5. The same failure pattern keeps repeating
Across these conversations, the same pattern surfaced again and again:
-
Early signals emerge internationally
-
Risk is discounted because the UK remains supplied
-
Preparation is deferred until formal UK confirmation
-
Sourcing, regulatory and logistics pressures collide
-
Patients experience avoidable disruption
Importers were clear: the problem is not regulation.
The problem is late readiness.
A shared conclusion
What struck me most is that these companies are not asking to move faster than the system allows.
They are asking to see earlier, so they can prepare responsibly.
Unlicensed imports work best when they are planned, proportionate and compliant, not reactive.
And preparation, almost without exception, depends on having a timely, real-time view of supply risk beyond the UK.
That is the common insight I keep hearing.
And it’s one worth paying attention to.